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Overrepresentation of Injection Drug Use Route of 
Infection Among Human Immunodeficiency Virus Long-
term Nonprogressors: A Nationwide, Retrospective Cohort 
Study in China, 1989–2016
Jing Han,1 Zunyou Wu,1,2 Jennifer M. McGoogan,1 Yurong Mao,1 Houlin Tang,1 Jian Li,1 Yan Zhao,1 Cong Jin,1 Roger Detels,2 Ron Brookmeyer,3  
Viviane D. Lima,4 and Julio S. G. Montaner4
1National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China; Departments of 2Epidemiology and 3Biostatistics, Fielding School of 
Public Health, University of California–Los Angeles; 4British Columbia Center for Excellence in HIV/AIDS, University of British Columbia, Vancouver, Canada
Background. Why some persons living with human immunodeficiency virus (HIV) (PLWH) progress quickly and others re-
main “healthy” for a decade or more without treatment remains a fundamental question of HIV pathology. We aimed to assess the 
epidemiological characteristics of HIV long-term nonprogressors (LTNPs) based on a cohort of PLWH in China observed between 
1989 and 2016.
Methods. We conducted a nationwide, retrospective cohort study among Chinese PLWH with HIV diagnosed before 1 January 
2008. Records were extracted from China’s national HIV/AIDS database on 30 June 2016. LTNPs were defined as those with AIDS-
free, antiretroviral therapy–naive survival, with CD4 cell counts consistently ≥500/μL for ≥8 years after diagnosis. Prevalence was 
calculated, characteristics were described, and determinants were assessed by means of logistic regression. Potential sources of bias 
were also investigated.
Results. Our cohort included 89 201 participants, of whom 1749 (2.0%) were categorized as LTNPs. The injection drug use 
(IDU) route of infection was reported by 70.7% of LTNPs, compared with only 37.1% of non-LTNPs. The odds of LTNP status were 
greater among those infected via IDU (adjusted odds ratio [95% confidence interval], 2.28 [1.94–2.68]) and with HIV diagnosed in 
settings with large populations of persons who inject drugs (1.75 [1.51–2.02] for detention centers, 1.61 [1.39–1.87] for Yunnan, 1.94 
[1.62–2.31] for Guangdong, and 2.90 [2.09–4.02] for Xinjiang).
Conclusions. Overrepresentation of the IDU route of infection among LTNPs is a surprising finding worthy of further study, 
and this newly defined cohort may be particularly well suited to exploration of the molecular biological mechanisms underlying HIV 
long-term nonprogression.
Keywords. CD4 cell count; HIV slow progression; injection drug use; long-term nonprogression; opioids.
In the absence of treatment, progression from acute human im-
munodeficiency virus (HIV) infection to AIDS tends to occur 
within about a decade [1]. However, a small proportion of per-
sons living with HIV (PLWH) experience notably slower pro-
gression, maintaining high numbers of CD4+ T lymphocytes 
(CD4 cell counts) over a protracted period without the aid of 
antiretroviral therapy (ART). Individuals exhibiting this in-
frequent phenotype are commonly referred to as long-term 
nonprogressors (LTNPs) [2–5]. Because of variability in the 
definition of LTNPs [5], estimation of the prevalence of this rare 
phenotype has been challenging [6], but it is generally thought 
to be <5% [7–10].
Thus far, a preponderance of studies has been conducted 
in individual LTNPs or in very small LTNP cohorts in high-
income settings, such as Australia [11], Canada [12], France 
[7, 10], Italy [13], Spain [14], the United Kingdom [9], and the 
United States [8, 15], where HIV-1 subtype B is predominant 
[16]. Therefore, although LTNPs may hold important clues to 
mechanisms underlying the pathophysiology of HIV, which 
may aid in developing new treatment or prevention strategies 
(eg, finding new target epitopes for neutralizing antibodies 
or antiviral agents [17]), current evidence is limited by small 
samples in unique settings where host and viral genetics are rel-
atively lacking in diversity.
Thus, we sought to investigate LTNPs in China, a large, ethni-
cally diverse, middle-income country, where HIV genomic vari-
ability is very high [18]. To do this, we took advantage of China’s 
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National HIV/AIDS Comprehensive Response Information 
Management System (CRIMS), which has tracked every indi-
vidual with a diagnosis of HIV infection in the entire country 
since 1985 [19].
METHODS
Design and Setting
We conducted a nationwide, retrospective cohort study in 
China to investigate long-term nonprogression of HIV disease 
among Chinese persons with HIV diagnosed before 1 January 
2008. Data were extracted on 30 June 2016, so all participants 
were followed up for ≥8 years. None were excluded owing to 
loss to follow-up. Rather, all meeting study eligibility criteria 
were included regardless of the duration since the most recent 
follow-up visit. Figure 1 shows the design of our study.
Data Source
We used data extracted from CRIMS, a real-time, web-based 
information system managed by the National Center for AIDS/
STD Control and Prevention, Chinese Center for Disease 
Control and Prevention. As described elsewhere [19], CRIMS 
contains records for all individuals with an HIV diagnosis 
in China; there are no missing or duplicate cases because re-
porting is mandatory and records are linked to national iden-
tification numbers. Records contain contact and demographic 
information, testing and baseline clinical information, patient-
reported route of infection, dates and details of all follow-up 
visits, and other health-related information (eg, coinfections 
and comorbid conditions), as well as dates and causes of death. 
However, CRIMS does have some important limitations 
that must be noted. For example, CRIMS records do not 
contain estimated dates of infection or seroconversion. 
Therefore, PLWH often have already had HIV infection for 
some years at the time of diagnosis. Indeed, a recent study 
in China found a median duration of infection of 6.3 years 
before diagnosis [20]. This means that, in China, an indi-
vidual with CD4 cell counts consistently ≥500/μL without 
ART for >8 years, has probably been infected for even longer 
and remained “healthy.” Moreover, it was common during 
our study period for persons with newly diagnosed HIV 
with CD4 cell counts above the 200/μL, 350/μL, and 500/μL 
thresholds to remain untreated for some time [21]. Although 
clinical guidelines specified that CD4 cell count should be 
evaluated annually regardless of treatment status [22], this 
evaluation has been inconsistent and infrequent in practice, 
resulting in many CRIMS records containing few CD4 cell 
count results. Finally, clinical guidelines in China do not 
allow viral load (VL) testing until ≥6 months after ART ini-
tiation and only annually thereafter [22]. Hence, no VL data 
are available for any patient before ART initiation, and—as 
with CD4 cell counts—VL testing has been inconsistent and 
infrequent, and records contain few results. Moreover, aside 
from rare drug resistance test results, viral subtype and se-
quence data are not available.
171 833 Screened
(All HIV diagnoses before 1 January 2008)
82 632 (48.1%) Excluded
10 447 (12.6%) <15 y of  age
71 294 (86.3%) lacking CD4 cell counts
891 (1.1%) insucient information
19 084 (21.4%)
Included in subanalysis
for investigation of  potential
lead-time bias among patients with
baseline CD4 cell count ≥500/μL
≥8-y
Follow-up
89 201 (51.9%)
Included in analysis
87 452 (98.0%)
Not Long-Term
Non-Progressors
Non-LTNPs
1749 (2.0%)
Long-Term
Non-Progressors
LTNPs
Figure 1. Development of the study cohort. All persons living with human immunodeficiency virus (HIV) in China who had a date of HIV diagnosis before 1 January 2008 
were screened for study eligibility. A total of 89 201 (59.1%) were included in the analysis and categorized by their long-term nonprogressor (LTNP) status. A total of 1749 
LTNPs were found, for a prevalence of 2.0%. All 89 201 study participants were followed up until records were extracted on 30 June 2016, for ≥8 years or until death. To 
investigate potential lead-time bias caused by earlier diagnosis in some individuals than in others, a subanalysis was conducted among only those in the cohort with baseline 
CD4 cell counts ≥500/μL.
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Cohort Development
Development of the study cohort is shown in Figure 1. All 
CRIMS records with a date of HIV diagnosis before 1 January 
2008 were screened for study eligibility. Two inclusion criteria 
were applied: ≥15 years of age at HIV diagnosis (ie, age cutoff 
for adulthood according to China’s HIV clinical guidelines 
[22]) and CD4 cell counts. Records were excluded if they did 
not contain enough information to categorize participants by 
LTNP status. All eligible records were extracted on 30 June 
2016, which was 8 years after the latest possible diagnosis date.
Development of the Study Definition of LTNPs
Although a recent systematic review by Gurdasani et  al [5] 
found 159 unique definitions of HIV LTNPs in the literature, 
the common theme was that LTNPs remain asymptomatic with 
no AIDS-defining illness for a prolonged time (ie, the period 
of nonprogression) while retaining a high CD4 cell count (ie, 
the CD4 cell count threshold) in the absence of ART, although 
LTNPs may start ART or develop symptoms, progress to AIDS, 
or die after the period of nonprogression has been completed 
and still be considered LTNPs. However, the length of the 
nonprogression period and the level of the CD4 cell count 
threshold vary, and our data source has some important limita-
tions that required consideration.
We examined definitions used in similar published studies. 
For example, Madec et  al [7] used >8  years with CD4 cell 
counts >500/μL and Grabar et  al [10] used ≥8  years with 
CD4 cell counts ≥500/μL, whereas Okulicz et al [8] used both 
≥7  years and ≥10  years with CD4 cell counts ≥500/μL, and 
Mandalia et al [9] used ≥7 years and the stability of the slope 
of multiple CD4 cell counts. Most definitions captured in the 
review by Gurdasani et al [5] used a 10-year nonprogression 
period and a CD4 cell count threshold of 500/μL. Therefore, 
we too selected the ≥500/μL threshold but chose a somewhat 
shorter ≥8-year nonprogression period for our study, because 
HIV in China is often diagnosed late, a median of 6.3 years 
after infection [20].
We then put this into context with the data we had available 
to us in CRIMS, thereby defining the 2 major components of 
our LTNP definition. The first was duration of nonprogression 
≥8  years. To meet this criterion, CRIMS records were re-
quired to demonstrate a ≥8-year survival period after the 
date of diagnosis (which was before 1 January 2008) with (1) 
no HIV/AIDS symptoms or AIDS-defining illness and (2) 
no ART. After 8 years, evidence of ART, symptoms, AIDS, or 
death did not cause records to be excluded from categoriza-
tion as LTNPs.
The second component was CD4 cell count ≥500/μL. To meet 
this criterion, CRIMS records were required to contain (1) ≥2 
CD4 cell counts ≥500/μL and none <500/μL during the ≥8-year 
nonprogression period after the date of diagnosis, (2) ≥1 CD4 
cell count ≥500/μL after the ≥8-year nonprogression period was 
completed, and (3) a ≥1-year time interval between first ever 
and last (or most recent) CD4 cell count ≥500/μL.
To illustrate this definition, we present 7 hypothetical 
scenarios in Figure 2. Scenarios 1–4 describe generalized 
patients categorized as non-LTNPs for failure to meet ≥1 com-
ponent of the LTNP study definition. Scenarios 5–7 illustrate 
generalized patients categorized as LTNPs. Because scenarios 
1–4 (non-LTNPs) may have had a smaller chance of being 
categorized as LTNPs simply owing to later diagnosis, we also 
investigated the possibility of lead-time bias in our cohort.
Scenario 1
8-y Period of nonprogression
Scenario 2
Scenario 3
ART
ART
ART
ART Date of ART initiation
L
T
N
Ps
N
on
-L
T
N
Ps
Death before study end
Date of diagnosis
Date of CD4 cell count ≥500/μL
Date of CD4 cell count <500/μL
Scenario 4
Scenario 5
Scenario 6
Scenario 7
Time before diagnosis
Time after diagnosis
Alive at study end
Figure 2. Illustration of the study definition of long-term nonprogressors (LTNPs). Abbreviation: ART, antiretroviral therapy.
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Data Analysis
Categorical variables are presented as numbers and 
percentages, and prevalence comparisons were conducted 
using χ2 test, with 1 category for each variable used as a refer-
ence. Continuous variables are presented as median with in-
terquartile range (IQR) but not compared  for statistical test. 
Missing data were categorized as unknown but still included 
in the analyses. Observed time was calculated from the date of 
diagnosis to study end or death and expressed in person-years 
(PYs). Factors associated with LTNP status were investigated 
using univariable and multivariable logistic regression with 
results reported as odds ratios and 95% confidence intervals 
(CIs). Because of potential for lead-time bias—participants 
with HIV diagnosed earlier may have had a greater chance 
of being categorized as LTNPs—we repeated the logistic re-
gression analysis using only the subset of participants with 
baseline CD4 cell counts ≥500/μL. In addition, because of the 
potential for confounding bias owing to some key variables 
being related, we conducted 4 crossover stratified analyses 
using binary logistic regression, with LTNP status as the di-
chotomous dependent variable. All analyses were conducted 
using SPSS software (version 24.0; IBM).
Ethics
The protocol was approved by the institutional review board 
of the National Center for AIDS/STD Control and Prevention, 
Chinese Center for Disease Control and Prevention. Informed 
consent was not required because all individuals with HIV 
diagnosed in China sign written informed consent at diagnosis, 
allowing future use of their deidentified data for epidemiolog-
ical studies.
RESULTS
As shown in Figure 1, a total of 171 833 CRIMS records were 
screened, and a total of 89 201 (51.9%) participants were in-
cluded in our cohort. Among the 82 632 who were excluded, 
10 447 (12.6%) were <15 years of age, 71 294 (86.3%) lacked 
CD4 cell count results, and 891 (1.1%) had insufficient in-
formation in their records to categorize them as LTNPs or 
non-LTNPs.
Characteristics of study participants are presented in Table 1. 
At baseline (diagnosis), most participants were aged 25–34 years 
(43.6%) or ≥35  years (42.3%), male (68.0%), of Han ethnicity 
(73.8%), and married (52.6%). A majority had junior high school 
education or less (junior high, 43.4%, primary school or less, 
40.8%) and worked as farmers (54.4%). The most frequent HIV 
infection routes were injection drug use (IDU; 37.8%) and het-
erosexual contact (33.4%). Most have HIV diagnosed at volun-
tary counseling and testing locations (28.6%) or detention centers 
(23.0%), in Yunnan (24.9%) or Henan (20.4%), and between 2005 
and 2008 (70.3%). Most had baseline CD4 cell counts <500/μL 
(≤199/μL, 32.0%; 200–349/μL, 25.1%; 350–499/μL, 21.5%).
A total of 1749 participants (of 89 201)  met the definition 
of LTNPs, for an overall, nationwide LTNP prevalence of 2.0%. 
The prevalence of LTNP status was higher among those who 
were aged 15–24 (3.8%) or 25–34 (2.5%) years, male (2.4%), 
ethnic Uygur (5.1%), never married (3.1%), and had home-
maker/unemployed (3.0%) or service industry worker (2.9%) as 
their occupation. LTNP status was also more prevalent among 
participants with an IDU infection route (3.7%) and diagnosis 
in detention centers (4.0%), in Yunnan (2.5%), Guangdong 
(3.9%), and Xinjiang (5.0%), and in the 1990–2004 period 
(3.3%). The median (IQR) observed time for non-LTNPs was 
8.8 (7.1–10.7) PYs and for LTNPs was a higher but comparable 
11.0 (9.7–13.0) PYs (Table 1).
Results of our investigation into factors associated with LTNP 
status are presented in Table 2. After adjustment for confounding, 
we found greater odds of LTNP status among participants who were 
younger (adjusted odds ratio [AOR] [95% CI] vs age ≥35 years, 
1.90 [1.66–2.17] for age 25–34 years and 3.34 [2.87–3.88] for age 
15–24 years), had an IDU route of infection (vs heterosexual con-
tact, 2.28 [1.94–2.68]), had HIV diagnosed in a detention center 
(vs a voluntary counseling and testing location, 1.75 [1.51–2.02]), 
a blood donation station (1.84 [1.41–2.39]), or as a part of a spe-
cial investigation (1.61 [1.32–1.96]), and in Yunnan (vs other prov-
inces, 1.61 [1.39–1.87]), Guangxi (1.46 [1.21–1.77]), Guangdong 
(1.94 [1.62–2.31]), or Xinjiang (2.90 [2.09–4.02]). The odds of 
LTNP status were lower for those of minority ethnicities other than 
Uygur (AOR [95% CI] vs Han, 0.66 [.57–.76]) and for those with 
heterosexual contact as their infection route (vs heterosexual con-
tact, 0.45 [.25–.80]). When diagnosis location was left out of the 
model, the odds of LTNP status were greater for those of Uygur 
ethnicity (AOR [95% CI] vs Han, 1.84 [1.59–2.12]).
Results of the subanalysis that included only participants 
with baseline CD4 cell counts ≥500/μL are presented in 
Table 3. After adjusting for confounding, we found greater odds 
of LTNP status among those who were younger (AOR [95% CI], 
1.56 [1.36–1.79] for age 25–34: years and 2.28 [1.94–2.67] for age 
15–24 years), had IDU (2.12 [1.79–2.50]) or blood products (1.61 
[1.14–2.28]) as their infection route, had HIV diagnosed in a de-
tention center (1.60 [1.38–1.86]), in a blood donation station (1.66 
[1.26–2.19]), or as a part of a special investigation (1.52 [1.24–1.88]), 
and in Yunnan (1.52 [1.31–1.78]), Guangxi (2.05 [1.68–2.49]), 
Guangdong (2.26 [1.87–2.73]), or Xinjiang (2.95 [2.08–4.18]). The 
odds of LTNP status were lower among other ethnicities (AOR 
[95% CI], 0.60 [.52–.70]) and those with homosexual contact as 
the infection route (0.45 [.25–.80]). When diagnosis location was 
left out of the model, the odds of LTNP status among those who 
reported their route of infection as blood products was no longer 
significantly elevated (AOR [95% CI], 0.91 [.71–1.17]).
Results of binary logistic regression analyses are presented 
in Tables 4–7. Among those with Uygur ethnicity, those with 
an IDU infection route had greater odds of LTNP status (AOR 
[95% CI], 2.18 [1.58–3.03]). However, among those with all other 
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Table 1. Characteristics of Study Participants in the Nationwide Cohort (China, 1989–2016) and Prevalence of Long-term Nonprogressor (LTNP) and Non-
LTNP Status
Characteristic
All Participants, 
No. (Column %)a
Participants, No. (Row %)a
P ValuebNon-LTNPs LTNPs 
Total sample 89 201 (100.0) 87 452 (98.0) 1749 (2.0) …
Baseline characteristics     
 Age group, y     
  ≥35 37 750 (42.3) 37 416 (99.1) 334 (0.9) … (Ref)
  25–34 38 933 (43.6) 37 997 (97.6) 936 (2.5) <.001
  15–24 12 518 (14.0) 12 039 (96.2) 479 (3.8) <.001
 Sex     
  Female 28 523 (32.0) 28 195 (98.9) 328 (1.1) … (Ref)
  Male 60 678 (68.0) 59 257 (97.7) 1421 (2.4) <.001
 Ethnicity     
  Han 65 849 (73.8) 64 693 (98.2) 1156 (1.8) … (Ref)
  Uygur 5319 (6.0) 5048 (94.9) 271 (5.1) <.001
  Otherc 15 741 (17.6) 15 476 (98.3) 265 (1.7) .5
  Unknown 2292 (2.6) 2235 (97.5) 57 (2.5) <.001
 Marital status     
  Married 46 943 (52.6) 46 340 (98.7) 603 (1.3) … (Ref)
  Never married 22 405 (25.1) 21 713 (96.9) 692 (3.1) <.001
  Divorced/widowed 17 686 (19.8) 17 332 (98.0) 354 (2.0) <.001
  Unknown 2167 (2.4) 2067 (95.4) 100 (4.6) <.001
 Education     
  Primary school or less 36 352 (40.8) 35 698 (98.2) 654 (1.8) … (Ref)
  Junior high school 38 754 (43.4) 37 921 (97.9) 833 (2.1) .001
  Senior high school or more 10 836 (12.1) 10 681 (98.6) 155 (1.4) .01
  Unknown 3259 (3.7) 3152 (96.7) 107 (3.3) <.001
 Occupation     
  Farmer 48 521 (54.4) 47 836 (98.6) 685 (1.4) … (Ref)
  Homemaker/unemployed 18 108 (20.3) 17 563 (97.0) 545 (3.0) <.001
  Service industry worker 4237 (4.7) 4114 (97.1) 123 (2.9) <.001
  Laborer 3910 (4.4) 3825 (97.8) 85 (2.2) <.001
  Government employee 3056 (3.4) 3025 (99.0) 31 (1.0) .07
  Otherd 6457 (7.2) 6329 (98.0) 128 (2.0) <.001
  Unknown 4912 (5.5) 4760 (96.9) 152 (3.1) <.001
 Route of infection     
  Heterosexual contact 29 809 (33.4) 29 518 (99.0) 291 (1.0) … (Ref)
  Injection drug use 33 715 (37.8) 32 478 (96.3) 1237 (3.7) <.001
  Blood productse 19 626 (22.0) 19 484 (99.3) 142 (0.7) .003
  Homosexual contact 2572 (2.9) 2559 (99.5) 13 (0.5) .02
  Unknown 3479 (3.9) 3413 (98.1) 66 (1.9) <.001
 Type of diagnosis site     
  VCT location 25 540 (28.6) 25 219 (98.7) 321 (1.3) … (Ref)
  Detention center 20 511 (23.0) 19 690 (96.0) 821 (4.0) .03
  Hospital/clinic 16 067 (18.0) 15 903 (99.0) 164 (1.0) <.001
  Blood donation station 8474 (9.5) 8382 (98.9) 92 (1.1) .21
  Investigation 7795 (8.7) 7635 (97.9) 160 (2.1) <.001
  Spouse/sex partner test 4278 (4.8) 4239 (99.1) 39 (0.9) .06
  Otherf 6536 (7.3) 6384 (97.7) 152 (2.3) <.001
 Location of diagnosis site     
  Otherg 24 656 (27.6) 24 352 (98.8) 304 (1.2) … (Ref)
  Yunnan 22 246 (24.9) 21 700 (97.5) 546 (2.5) <.001
  Henan 18 165 (20.4) 18 036 (99.3) 129 (0.7) <.001
  Guangxi 11 334 (12.7) 11 130 (98.2) 204 (1.8) <.001
  Guangdong 6587 (7.4) 6330 (96.1) 257 (3.9) <.001
  Xinjiang 6213 (7.0) 5904 (95.0) 309 (5.0) <.001
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ethnicities, those with IDU infection route also had greater odds 
of LTNP status (AOR [95% CI], 3.97 [3.45–4.57]; Table 4). Among 
those with an IDU infection route, those of Uygur ethnicity had 
greater odds of LTNP status (AOR [95% CI], 1.75 [1.50–2.04]), 
and among those with other infection routes, those of Uygur eth-
nicity also had greater odds of LTNP status (3.44 [2.55–4.66]) 
(Table 5). Among participants in all 3 age groups, those with 
IDU infection route had greater odds of LTNP status (AOR [95% 
CI], 3.64 [2.90–4.57] for age 15–24  years, 3.33 [2.77–4.01] for 
age 25–34 years, and 4.26 [3.17–5.74] for age ≥35 years), as did 
those of Uygur ethnicity (2.19 [1.72–6.67] for age 15–24 years, 
2.23 [1.86–2.69] for age 25–34  years, and 3.25 [2.23–4.75] for 
age ≥35 years) (Table 6). Finally, among participants with HIV 
diagnosed in 1990–2004 or in 2005–2008, the odds of LTNP 
status were greater among those with an IDU infection route 
(AOR [95% CI], 3.27 [2.54–4.22] for diagnosis in 1990–2004 and 
2.85 [2.44–3.33] for diagnosis in 2005–2008) and those of Uygur 
ethnicity (5.33 [4.40–6.46] for diagnosis in 1990–2004 and 2.28 
[1.87–2.78] for diagnosis in 2005–2008) (Table 7).
DISCUSSION
The present study represents the first-ever establishment of 
a large nationwide cohort of LTNPs in China—an ethnically 
diverse middle-income country where HIV genetic diversity 
is substantial [18]. We found that persons who reported their 
route of infection as IDU were overrepresented among this 
Chinese LTNP cohort at 70.7% (1237 of 1749), compared with 
37.3% (32 478 of 87 452) among non-LTNPs. In multivariable 
analyses, the IDU infection route was associated with >2-fold 
higher odds of LTNP status. Moreover, HIV diagnosis in 
settings where persons who inject drugs (PWID) were more 
concentrated—detention centers [23], and Yunnan, Guangxi, 
Guangdong, or Xinjiang provinces [24]—was also associated 
with greater odds of LTNP status.
These results were unexpected, because an extensive lit-
erature documents epidemiological, clinical, in vivo, and in 
vitro evidence of opioids acting as an accelerator of HIV path-
ogenesis owing to negative effects on host immune function 
[25–32]. We found only 1 small study in Sweden documenting 
slower HIV disease progression among PWID [33]. A more re-
cent, larger study in Hubei, China, found similar results [34]. 
However, in both studies, the comparison group was not non-
PWID. Rather, it was men who have sex with men (MSM) [33, 
34]. In China, where non-B subtype viral strains are dominant, 
different subtypes and circulating recombinant forms (CRFs; 
eg, CRF01_AE, CRF07_BC, and CRF08_BC) are known to 
vary in prevalence among the different key populations owing 
Characteristic
All Participants, 
No. (Column %)a
Participants, No. (Row %)a
P ValuebNon-LTNPs LTNPs 
 Year of diagnosis     
  1990–2004 26 464 (29.7) 25 584 (96.7) 880 (3.3) … (Ref)
  2005–2008 62 737 (70.3) 61 868 (98.6) 869 (1.4) <.001
 Baseline CD4 cell count     
  ≤199/μL 28 559 (32.0) 28 559 (100) 0 (0.0) …
  200–349/μL 22 393 (25.1) 22 393 (100) 0 (0.0) …
  350–499/μL 19 165 (21.5) 19 165 (100) 0 (0.0) …
  ≥500/μL 19 084 (21.4) 17 335 (90.8) 1749 (9.2) …
  Median (IQR), cells/μL  306 (152–468) 301 (149–456) 738 (611–896) …
Follow-up characteristics     
 Observation time, PYs     
  All participants     
   Median (IQR) 8.9 (7.2–10.7) 8.8 (7.1–10.7) 11.0 (9.7–13.0) …
   Range 0.1–26.5 0.1–26.5 8.0–23.6 …
  Participants with baseline CD4 cell count ≥500/μL     
   Median (IQR) 9.0 (7.9–10.8) 8.9 (7.8–10.5) 11.0 (9.7–13.0) …
   Range 0.1–23.6 0.1–20.0 8.0–23.6 …
 Median participant CD4 cell count, cells/μL     
   Median (IQR) 289 (151–430) 284 (147–420) 732 (612–826) …
   Range 2–1980 2–1980 504–1670 …
Abbreviations: IQR, interquartile range; LTNPs, long-term nonprogressors; PYs, person-years; Ref, reference category; VCT, voluntary counseling and testing.
aData represent no. (%) of participants unless otherwise specified.
bCategorical variables were compared between categories using χ2 tests. 
cThe “Other” category for the ethnicity variable includes the remaining 49 minority ethnicities recognized by the Chinese Government.
dThe “Other” category for the occupation variable includes all other occupations as well as students.
eThe “Blood products” category encompasses infection via either blood product donation or receipt.
fThe “Other” category for the type of diagnosis site variable includes enlisted physical, exit and entry physical, premarital, occupational exposure, and entertainment place examinations.
gThe “Other” category for the location of diagnosis site variable includes the remaining 27 provinces in China.
Table 1. Continued
HIV Long-term Nonprogressors in China • ofid • 7
to their relative abundance in sexual and needle-sharing 
networks [35–38]. Thus, it is possible that our finding of over-
representation of the IDU infection route among LTNPs in 
China may be related to viral genetic factors. This idea is fur-
ther bolstered by the observation that MSM had lower odds of 
being LTNPs.
We found that LTNPs in our cohort were roughly 80% more 
likely to have been diagnosed in a detention center, and 50%–
190% more likely to have had HIV diagnosed in Yunnan, Guangxi, 
Guangdong, and Xinjiang. These findings make sense in the China 
context, because confinement of drug users in detention centers 
has been common practice for several decades [39], and because 
China’s HIV epidemic among drug users is well known to have 
originated in Yunnan and expanded over drug trafficking routes 
to Guangxi, Guangdong, and Xinjiang [24]. Recent HIV genomic 
studies have revealed the chronology and geography of the spread 
of unique variants of the virus that mirror the expansion of China’s 
HIV epidemic among drug users and are distinct from HIV ge-
netic variants more common in other risk groups (eg, MSM) [35–
38]. We believe that these findings also suggest the influence of 
viral factors in our cohort that require further investigation.
In the present study, we have largely focused on a first-time, 
epidemiological characterization of this cohort. To this end, 
we have found, for example, that younger age and Uygur 
ethnicity were associated with greater odds of LTNP status, 
whereas other minority groups had lesser odds. Although 1 
study in the United States has found an association between 
LTNP status and ethnicity [8], other studies have found no 
such association [4, 9, 13]. The notable association between 
Uygur ethnicity and greater odds of LTNP status may be 
Table 2. Factors Associated with Long-term Nonprogressor Status: Results of Univariable and Multivariable Logistic Regression Analyses in a Nationwide 
Cohort (China, 1989–2016)
Variable
Odds Ratio (95% Confidence Interval)
Unadjusted Adjusteda Adjustedb
Age group, y    
 ≥35 1.00 1.00 1.00
 25–34 2.76 (2.43–3.13) 1.94 (1.70–2.21) 1.90 (1.66–2.17)
 15–24 4.46 (3.87–5.13) 3.38 (2.91–3.93) 3.34 (2.87–3.88)
Sex    
 Female 1.00 1.00 1.00
 Male 2.06 (1.83–2.33) 1.26 (1.10–1.44) 1.23 (1.07–1.41)
Ethnicity    
 Han 1.00 1.00 1.00
 Uygur 3.00 (2.62–3.44) 1.84 (1.59–2.12) 0.97 (.70–1.34)
 Other 0.96 (.84–1.10) 0.64 (.56–.74) 0.66 (.57–.76)
 Unknown 1.43 (1.09–1.87) 1.25 (.90–1.72) 1.16 (.83–1.62)
Route of infection    
 Heterosexual contact 1.00 1.00 1.00
 Injection drug use 3.86 (3.40–4.39) 2.41 (2.05–2.83) 2.28 (1.94–2.68)
 Blood products 0.74 (.60–.90) 0.79 (.62–1.00) 1.03 (.75–1.43)
 Homosexual contact 0.52 (.30–.90) 0.35 (.20–.61) 0.45 (.25–.80)
 Unknown 1.96 (1.50–2.57) 1.45 (1.06–2.00) 1.37 (.99–1.90)
Type of diagnosis site    
 VCT location 1.00 1.00 1.00
 Detention center 3.28 (2.88–3.73) 1.74 (1.51–2.01) 1.75 (1.51–2.02)
 Hospital/clinic 0.81 (.67–.98) 0.94 (.77–1.14) 0.95 (.78–1.15)
 Blood donation station 0.86 (.68–1.09) 1.77 (1.36–2.29) 1.84 (1.41–2.39)
 Investigation 1.65 (1.36–1.99) 1.67 (1.37–2.03) 1.61 (1.32–1.96)
 Spouse/sex partner test 0.72 (.52–1.01) 1.16 (.82–1.65) 1.27 (.90–1.81)
 Other 1.87 (1.54–2.27) 1.30 (1.06–1.58) 1.25 (1.03–1.53)
Location of diagnosis    
 Other 1.00 … 1.00
 Yunnan 2.02 (1.75–2.32) … 1.61 (1.39–1.87)
 Henan 0.57 (.47–.70) … 1.06 (.78–1.44)
 Guangxi 1.47 (1.23–1.76) … 1.46 (1.21–1.77)
 Guangdong 3.25 (2.75–3.85) … 1.94 (1.62–2.31)
 Xinjiang 4.19 (3.57–4.92) … 2.90 (2.09–4.02)
Abbreviation: VCT, voluntary counseling and testing.
aModel included all shown variables except location of diagnosis.
bModel included all shown variables.
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explained, at least in part, by a study comparing the CD4 cell 
counts of healthy adults of the Uygur minority group and 
ethnic Han Chinese, which found that those of Uygur eth-
nicity have significantly higher normal CD4 cell counts [40].
Although our finding of a 2.0% prevalence for the LTNP phe-
notype is below that reported by some, such as Madec et al [7] 
in France and Okulicz et al [8] in the United States, it is well 
above that reported by others, including Mandalia et al [9] in 
Table 3. Investigation of Potential Lead-Time Bias: Results of Univariate and Multivariate Logistic Regression Analyses Among Those With Baseline CD4 
Cell Counts ≥500/μL in a Nationwide Cohort (China, 1989–2016)
Variable
Odds Ratio (95% Confidence Interval)
Unadjusted Adjusteda Adjustedb 
Age group, y    
 ≥35 1.00 1.00 1.00
 25–34 1.99 (1.75–2.26) 1.60 (1.40–1.84) 1.56 (1.36–1.79)
 15–24 2.51 (2.17–2.90) 2.32 (1.98–2.72) 2.28 (1.94–2.67)
Sex    
 Female 1.00 1.00 1.00
 Male 1.95 (1.73–2.21) 1.31 (1.14–1.51) 1.28 (1.11–1.48)
Ethnicity    
 Han 1.00 1.00 1.00
 Uygur 1.85 (1.60–2.13) 1.36 (1.17–1.58) 0.73 (.51–1.04)
 Other 0.78 (.68–.90) 0.56 (.49–.65) 0.60 (.52–.70)
 Unknown 1.43 (1.07–1.89) 1.44 (1.01–2.07) 1.24 (.86–1.79)
Route of infection    
 Heterosexual contact 1.00 1.00 1.00
 Injection drug use 3.07 (2.69–3.50) 2.30 (1.95–2.71) 2.12 (1.79–2.50)
 Blood products 0.88 (.72–1.08) 0.91 (.71–1.17) 1.61 (1.14–2.28)
 Homosexual contact 0.49 (.28–.85) 0.35 (.20–.62) 0.45 (.25–.80)
 Unknown 1.86 (1.41–2.46) 1.33 (.94–1.88) 1.25 (.88–1.78)
Type of diagnosis site    
 VCT location 1.00 1.00 1.00
 Detention center 2.58 (2.25–2.96) 1.63 (1.41–1.88) 1.60 (1.38–1.86)
 Hospital/clinic 1.01 (.83–1.22) 1.19 (.97–1.45) 1.14 (.93–1.40)
 Blood donation station 0.89 (.70–1.13) 1.61 (1.22–2.12) 1.66 (1.26–2.19)
 Investigation 1.41 (1.16–1.72) 1.50 (1.22–1.84) 1.52 (1.24–1.88)
 Spouse/sex partner test 0.71 (.50–.99) 1.17 (.82–1.68) 1.37 (.96–1.97)
 Other 1.35 (1.10–1.65) 1.13 (.92–1.39) 1.11 (.90–1.37)
Location of diagnosis    
 Other 1.00 … 1.00
 Yunnan 1.63 (1.41–1.88) … 1.52 (1.31–1.78)
 Henan 0.61 (.49–.75) … 0.74 (.53–1.02)
 Guangxi 2.12 (1.76–2.55) … 2.05 (1.68–2.49)
 Guangdong 3.39 (2.84–4.05) … 2.26 (1.87–2.73)
 Xinjiang 2.81 (2.37–3.32) … 2.95 (2.08–4.18)
Abbreviation: VCT: voluntary counseling and testing.
aModel included all shown variables except location of diagnosis.
bModel included all shown variables.
Table 4. Investigation of Potential Confounding Bias: Results of Binary Logistic Regression Evaluating Ethnicity Versus Route of Infection in a Nationwide 
Cohort (China, 1989–2016)
Route of Infection
Uygur All Other Ethnicities
Participants, No. (%) OR (95% CI) P Value Participants, No. (%) OR (95% CI) P Value
Heterosexual contact 45 (2.9) 1.00 … 246 (0.9) 1.00 …
Injection drug use 222 (6.2) 2.18 (1.58–3.03) <.001 1015 (3.4) 3.97 (3.45–4.57) <.001
Blood products 0 (0.0) … … 142 (0.7) 0.83 (.67–1.02) .08
Homosexual contact 0 (0.0) … … 13 (0.5) 0.58 (.33–1.01) .06
Unknown 4 (2.0) 0.67 (.24–1.90) .46 62 (1.9) 2.20 (1.66–2.91) <.001
Abbreviations: CI, confidence interval; OR, odds ratio.
HIV Long-term Nonprogressors in China • ofid • 9
the United Kingdom. However, it is likely that differences in 
prevalence are attributable, at least in part, to varying definitions 
of LTNPs and study design, and as such, these differences may 
not represent meaningful interpopulation variability [5, 6]. 
Nevertheless, the study of this rare phenotype is important be-
cause discovery of variations in host and viral factors associ-
ated with long-term nonprogression of HIV infection further 
our understanding of HIV biology and could be invaluable to 
the development of next-generation prevention and treatment 
strategies [1–6, 17].
The large size and nationwide scope of our cohort were impor-
tant strengths of our study. However, results should be interpreted 
with caution, because our study had several important limitations. 
First, our data source had some crucial limitations, described in 
the Methods. Second, the retrospective cohort design precluded 
any examination of causality. Third, because the route of HIV in-
fection variable relied partly on self-reporting by patients at time 
of diagnosis (infection route is also verified by epidemiologists 
during routine case investigation), social desirability and recall 
bias may have led to misclassification of participants and there-
fore overrepresentation or underrepresentation of exposures. 
Fourth, we did not have access to the dates, or even estimated 
dates, of infection or seroconversion and had to rely on dates 
of diagnosis instead. Although it is likely that LTNP prevalence 
was underestimated as a result, because the seroconversion date 
always preceded the diagnosis date, this may have also caused 
some lead-time bias because PLWH with earlier diagnoses may 
have had increased opportunity to be categorized as LTNPs. 
However, we found that median follow-up time was similar be-
tween LTNPs and non-LTNPs (11.0 vs 8.8 PYs) and between 
those reporting the IDU infection route and those reporting 
all other routes (8.9 [IQR, 6.9–10.8] vs 8.8 [7.5–10.7] PYs; data 
not shown). Furthermore, when we conducted the subanalysis 
using only those with HIV diagnosed “early” (ie, when the base-
line CD4 cell count was still ≥500/μL), our finding of overrep-
resentation of the IDU route of infection among LTNPs and 
greater odds of LTNP status among those who reported IDU 
as their infection route did not change. Finally, the interrelated-
ness of several variables examined (eg, most persons in China 
of Uygur ethnicity live in Xinjiang province) may have caused 
some confounding bias. However, when we conducted the 
crossover stratified analyses using binary logistic regression, we 
found that the IDU route of infection was a robust predictor of 
LTNP status.
In conclusion, we provide a first-ever characterization of a 
nationwide cohort of 1749 LTNP in China who have remained 
Table 6. Investigation of Potential Confounding Bias: Results of Binary Logistic Regression Evaluating Age Versus Route of Infection and Ethnicity in a 
Nationwide Cohort (China, 1989–2016)
Route of Infection and Ethnicity
Participants Aged 15–24 y Participants Aged 25–34 y Participants Aged ≥35 y
No. (%) OR (CI) P Value No. (%) OR (CI) P Value No. (%) OR (CI) P Value
Route of infection          
 Heterosexual contact 97 (1.8) 1.00 … 135 (1.1) 1.00 … 59 (0.5) 1.00 …
 Injection drug use 359 (6.4) 3.64 (2.90–4.57) <.001 705 (3.6) 3.33 (2.77–4.01) <.001 173 (2.0) 4.26 (3.17–5.74) <.001
 Blood products 3 (0.8) 0.45 (.14–1.41) .17 64 (1.3) 1.16 (.86–1.57) .32 75 (0.5) 1.11 (.79–1.56) .55
 Homosexual contact 4 (0.5) 0.28 (.10–.76) .01 9 (0.9) 0.79 (.40–1.55) .49 0 (0.0) … …
 Unknown 16 (2.9) 1.60 (.94–2.74) .09 23 (1.5) 1.33 (.85–2.07) .21 27 (2.0) 4.21 (2.66–6.67) <.001
Ethnicity          
 Han 286 (3.8) 1.00 … 616 (2.3) 1.00 … 254 (0.8) 1.00 …
 Uygur 94 (7.9) 2.19 (1.72–6.67) <.001 146 (5.0) 2.23 (1.86–2.69) <.001 31 (2.6) 3.25 (2.23–4.75) <.001
 Other 83 (2.4) 0.63 (.49–.81) <.001 150 (1.9) 0.82 (.69–.99) .04 32 (0.7) 0.90 (.62–1.30) .58
 Unknown 16 (4.5) 1.20 (.72–2.01) .48 24 (2.1) 0.93 (.61–1.40) .71 17 (2.1) 2.64 (1.61–4.33) <.001
Abbreviations: CI, confidence interval; OR, odds ratio.
Table 5. Investigation of Potential Confounding Bias: Results of Binary Logistic Regression Evaluating Route of Infection Versus Ethnicity in a Nationwide 
Cohort (China, 1989–2016)
Ethnicity
Injection Drug Use All Other Routes
Participants, No. (%) OR (CI) P Value Participants, No. (%) OR (CI) P Value
Han 786 (3.6) 1.00 … 370 (0.8) 1.00 …
Uygur 222 (6.2) 1.75 (1.50–2.04) <.001 49 (2.8) 3.44 (2.55–4.66) <.001
Other 15 (3.9) 0.71 (.61–.83) <.001 42 (2.2) 0.81 (.60–1.08) .16
Unknown 786 (3.6) 1.07 (.64–1.81) .79 370 (0.8) 2.67 (1.94–3.69) <.001
Abbreviations: CI, confidence interval; OR, odds ratio.
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AIDS-free for ≥8  years without treatment. Our finding of 
overrepresentation of the IDU route of infection among 
LTNPs, while seemingly contradicting a large literature that 
supports opioids as an accelerator of HIV disease progres-
sion, makes sense in light of the spatiotemporal development 
of China’s HIV epidemic among PWID and suggests that 
perhaps a unique genetic characteristic of the viral strains 
circulating among the PWID population in China could be 
a driver of long-term nonprogression. However, both viral 
and host factors are known to play a role in determining the 
rate of HIV disease progression. Nevertheless, this unique 
cohort of LTNPs in a setting where viral genetic diversity is 
very high warrants further study because it could point to 
new paths toward the advancement of HIV treatment and 
prevention.
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